There's some discussion on medical blogs that this is a result of Zofran going generic-- it's been on the market 20 years and GSK just came across this single-center study... and wants to threaten it's generic competitors.
http://drwes.blogspot.com/2011/09/f...pot/TuRAx+(Dr.+Wes)&utm_content=Google+Reader
http://www.epmonthly.com/whitecoat/2011/09/fda-zofran-may-be-deadly/
http://drwes.blogspot.com/2011/09/f...pot/TuRAx+(Dr.+Wes)&utm_content=Google+Reader
http://www.epmonthly.com/whitecoat/2011/09/fda-zofran-may-be-deadly/